Patient-specific factors that influence choice include: Concurrent diabetes : Patients with type 2 diabetes may have broader access through NHS prescribing pathways BMI and weight loss goals : Higher BMI patients may benefit from agents with greater weight loss efficacy Tolerability : Previous experience with gastrointestinal side effects may guide selection Injection preference : Some patients strongly prefer weekly over daily injections, or oral over injectable formulations Cardiovascular disease : Certain GLP-1 agonists have proven cardiovascular benefits, which may be relevant for high-risk patients Ultimately, the choice should be individualised through shared decision-making between patient and clinician, considering the available evidence, licensed indications, local prescribing policies, and patient preferences
Will buy again.
Some older GLP-1 drugs have been discontinued or removed from the market, but the drug class remains very active
An examination of user reviews finds that people continue off-label Ozempic when it delivers results, even if side effects persist
My hairdresser mentioned it cautiously one day, asking if I was doing okay, and that was the push I needed to find a solution
How large (generous) is the Part D plan's formulary or drug list